Phase I studies demonstrated that GM-CSF secreting vaccines induced delayed-type hypersensitivity responses to autologous tumor cells and that vaccination sites showed brisk infiltrates of dendritic cells, macrophages, eosinophils, and lymphocytes contributing to enhanced tumor antigen presentation and ultimately promoting anti-tumor immunity (3–9). This evidence concerns the gene CSF2 and neoplasm.